+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clozapine resistance: augmentation strategies

Clozapine resistance: augmentation strategies

European Neuropsychopharmacology 22(3): 165-182

Clozapine (CLZ) is not effective in more than 50% of treatment-resistant schizophrenic patients. In these cases, several pharmacological strategies are used in clinical practice, with different levels of evidence for both safety and efficacy. In the present paper we critically reviewed literature data regarding the efficacy and safety of adjunctive agents in CLZ-resistant schizophrenics. The following classes of agents were considered: 1) antipsychotics, 2) antidepressants, 3) mood stabilizers, 4) other agents (e.g. fatty acid supplement and glutamatergic agents), 5) electroconvulsive therapy (ECT). For lamotrigine and risperidone sufficient data were available to perform a meta-analysis. A Medline literature search covering a 20-year period was performed. For the meta-analysis, data were entered and analyzed with the Cochrane Collaboration Review Manager Software (RevMan version 5). 62 pertinent studies were identified, including 1556 schizophrenic or schizoaffective patients. Among treatments investigated, there is evidence for CLZ augmentation with 1) amisulpride and aripiprazole, 2) mirtazapine and 3) ethyl eicosapentaenoic acid (E-EPA). Although promising, ECT augmentation needs further validation. The meta-analyses did not support either the use of risperidone or lamotrigine as CLZ adjunct. Overall, there is scarce evidence of efficacy and safety as regards adjunctive strategies for CLZ-resistant patients. However, several limitations do not allow to draw any definitive conclusion; among these we underline the small sample size of clinical trials, the variable definitions of CLZ resistance, the heterogeneity of outcome measures and methodological designs.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052147005

Download citation: RISBibTeXText

PMID: 21906915

DOI: 10.1016/j.euroneuro.2011.08.005

Related references

Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of Psychopharmacology 33(4): 423-435, 2019

Clozapine resistance--augmentation strategies. European Neuropsychopharmacology 23(4): 338, 2013

Somatic augmentation strategies in clozapine resistance--what facts?. Clinical Neuropharmacology 29(1): 34-44, 2006

Clozapine resistan Augmentation strategies. 2011

Augmentation strategies in clozapine-resistant schizophrenia. Cns Drugs 19(10): 843-872, 2005

When symptoms persist: Clozapine augmentation strategies. Schizophrenia Bulletin 27(4): 615-628, 2001

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clinical Neuropharmacology 29(1): 28-33, 2006

Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry 47(7): 231-238, 2015

Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment. Turk Psikiyatri Dergisi 25(3): 201-211, 2014

Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Australian and new Zealand Journal of Psychiatry 52(8): 751-767, 2018

Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opinion on PharmacoTherapy 15(16): 2329-2345, 2014

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 38(5): 1003-1011, 2012

Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. Journal of Psychopharmacology 30(5): 436-443, 2016

Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms. Pharmacopsychiatry 40(5): 202-203, 2007

ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research 105: 23-32, 2018